BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009;6:207-218. [PMID: 19333227 DOI: 10.1038/nrclinonc.2009.16] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani M. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer 2017;117:1269-77. [PMID: 29065426 DOI: 10.1038/bjc.2017.289] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
2 Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, Iacobelli S, Tampellini M, Durando X, Mormont M, Waterhouse J, Lévi FA. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer 2012;131:2684-92. [DOI: 10.1002/ijc.27574] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
3 Xu Q, Guo L, Gu X, Zhang B, Hu X, Zhang J, Chen J, Wang Y, Chen C, Gao B, Kuang Y, Wang S. Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12. Biomaterials 2012;33:3909-18. [PMID: 22374455 DOI: 10.1016/j.biomaterials.2012.02.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
4 Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. Journal of Controlled Release 2015;199:72-83. [DOI: 10.1016/j.jconrel.2014.11.031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
5 Seki K, Tsuduki Y, Ioroi T, Yamane M, Yamauchi H, Shiraishi Y, Ogawa T, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Yamamori M, Kuwahara A, Okamura N, Sakaeda T. Serum lactate dehydrogenase levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2014;11:641-5. [PMID: 24782655 DOI: 10.7150/ijms.7643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 Yue B, Gao R, Wang Z, Dou W. Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy. Front Cell Infect Microbiol 2021;11:710945. [PMID: 34722328 DOI: 10.3389/fcimb.2021.710945] [Reference Citation Analysis]
7 Sebio A, Stintzing S, Stremitzer S, Zhang W, Lenz H. Panitumumab: leading to better overall survival in metastatic colorectal cancer? Expert Opinion on Biological Therapy 2014;14:535-48. [DOI: 10.1517/14712598.2014.894502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Wang N, Guan QL, Jiang L, Zhou X, Gao C, Yang HT. Cisplatin plus 5-fluorouracil/leucovorin versus oxaliplatin plus 5-fluorouracil/leucovorin in the treatment of advanced gastric cancer: a systematic review. Shijie Huaren Xiaohua Zazhi 2009; 17(30): 3148-3154 [DOI: 10.11569/wcjd.v17.i30.3148] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, Chowhan N, Ramanathan RK, Keaton M, Hainsworth JD, Childs BH. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol 2014;25:1172-8. [PMID: 24608198 DOI: 10.1093/annonc/mdu107] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
10 Yue B, Gao R, Lv C, Yu Z, Wang H, Geng X, Wang Z, Dou W. Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase. Front Pharmacol 2021;12:774560. [PMID: 34795594 DOI: 10.3389/fphar.2021.774560] [Reference Citation Analysis]
11 Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2011;8:332-8. [PMID: 21611115 DOI: 10.7150/ijms.8.332] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
12 Keefe DMK, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 2012;9:98-109. [DOI: 10.1038/nrclinonc.2011.192] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
13 Tam HH, Cook GJ, Chau I, Drake B, Zerizer I, Du Y, Cunningham D, Koh D, Chua SS. The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. Clinical Nuclear Medicine 2015;40:e259-64. [DOI: 10.1097/rlu.0000000000000744] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010;11:373-382. [PMID: 20171141 DOI: 10.1016/s1470-2045(09)70341-9] [Cited by in Crossref: 85] [Cited by in F6Publishing: 38] [Article Influence: 7.1] [Reference Citation Analysis]
15 Li Y, Wang Y, Liu Z, Guo X, Miao Z, Ma S. Atractylenolide I Induces Apoptosis and Suppresses Glycolysis by Blocking the JAK2/STAT3 Signaling Pathway in Colorectal Cancer Cells. Front Pharmacol 2020;11:273. [PMID: 32273843 DOI: 10.3389/fphar.2020.00273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
16 Kochi M, Ichikawa W, Meguro E, Shibata H, Fukui T, Nagase M, Hoshino Y, Takeuchi M, Fujii M, Nakajima T. Phase II study of FOLFOX4 with "wait and go" strategy as first-line treatment for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2011;68:1215-1222. [PMID: 21416138 DOI: 10.1007/s00280-011-1605-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Levin G, Shirvan A, Grimberg H, Reshef A, Yogev-Falach M, Cohen A, Ziv I. Novel fluorescence molecular imaging of chemotherapy-induced intestinal apoptosis. J Biomed Opt 2009;14:054019. [PMID: 19895121 DOI: 10.1117/1.3253303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
18 Dia VP, Gonzalez de Mejia E. Lunasin induces apoptosis and modifies the expression of genes associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells. Mol Nutr Food Res 2011;55:623-34. [PMID: 21462330 DOI: 10.1002/mnfr.201000419] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
19 Wei Q, Zhang B, Li P, Wen X, Yang J. Maslinic Acid Inhibits Colon Tumorigenesis by the AMPK-mTOR Signaling Pathway. J Agric Food Chem 2019;67:4259-72. [PMID: 30913881 DOI: 10.1021/acs.jafc.9b00170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
20 Jiang W, Ji M. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Semin Cancer Biol 2019;59:3-22. [PMID: 30943434 DOI: 10.1016/j.semcancer.2019.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
21 Salvador-Martín S, García-González X, García MI, Blanco C, García-Alfonso P, Robles L, Grávalos C, Pachón V, Longo F, Martínez V, Sanjurjo-Sáez M, López-Fernández LA. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. Pharmacol Res 2018;136:133-9. [PMID: 30213564 DOI: 10.1016/j.phrs.2018.08.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
22 Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 2011;58:85-92. [PMID: 21482957 DOI: 10.1161/HYPERTENSIONAHA.110.168120] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
23 Yang Y, Zhao L, Lei L, Lau WB, Lau B, Yang Q, Le X, Yang H, Wang C, Luo Z, Xuan Y, Chen Y, Deng X, Xu L, Feng M, Yi T, Zhao X, Wei Y, Zhou S. LncRNAs: the bridge linking RNA and colorectal cancer. Oncotarget 2017;8:12517-32. [PMID: 27888635 DOI: 10.18632/oncotarget.13573] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
24 Weidlich S, Walsh K, Crowther D, Burczynski ME, Feuerstein G, Carey FA, Steele RJ, Wolf CR, Miele G, Smith G. Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Br J Cancer 2011;105:246-54. [PMID: 21712828 DOI: 10.1038/bjc.2011.197] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
25 Gerber PA, Buhren BA, Kürle S, Homey B. [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects]. Hautarzt 2010;61:654-61. [PMID: 20628713 DOI: 10.1007/s00105-010-1943-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Okamura N, Yamamori M, Tamura T, Sakaeda T. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011;8:210-5. [PMID: 21448307 DOI: 10.7150/ijms.8.210] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
27 Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer 2018;17:85-96. [PMID: 29576427 DOI: 10.1016/j.clcc.2017.12.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
28 Curtin JC. Novel drug discovery opportunities for colorectal cancer. Expert Opin Drug Discov. 2013;8:1153-1164. [PMID: 23768167 DOI: 10.1517/17460441.2013.807249] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
29 Lamberti M, Porto S, Zappavigna S, Stiuso P, Tirino V, Desiderio V, Mele L, Caraglia M. Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: clinical and occupational implications. Int J Oncol 2015;46:1893-900. [PMID: 25709090 DOI: 10.3892/ijo.2015.2904] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
30 Shao Q, Xu J, Deng R, Wei W, Zhou B, Yue C, Zhu M, Huang X, Zhu H. Long non-coding RNA-422 acts as a tumor suppressor in colorectal cancer. Biochemical and Biophysical Research Communications 2018;495:539-45. [DOI: 10.1016/j.bbrc.2017.10.076] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
31 Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Target Oncol 2016;11:293-308. [PMID: 26687849 DOI: 10.1007/s11523-015-0400-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
32 Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2014;22:1223-31. [PMID: 24362907 DOI: 10.1007/s00520-013-2075-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 6.7] [Reference Citation Analysis]
33 Siemerink EJ, Drenth AF, Mulder NH, Plukker JT, Hospers GA. Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer. Gastric Cancer 2010;13:95-100. [PMID: 20602196 DOI: 10.1007/s10120-010-0545-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Vidnes TK, Wahl AK, Andersen MH. Patient experiences following liver transplantation due to liver metastases from colorectal cancer. European Journal of Oncology Nursing 2013;17:269-74. [DOI: 10.1016/j.ejon.2012.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
35 Gu X, Wei Y, Fan Q, Sun H, Cheng R, Zhong Z, Deng C. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo. J Control Release 2019;301:110-8. [PMID: 30898610 DOI: 10.1016/j.jconrel.2019.03.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
36 Li H, Wang P, Sun Q, Ding WX, Yin XM, Sobol RW, Stolz DB, Yu J, Zhang L. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1. Cancer Res. 2011;71:3625-3634. [PMID: 21444671 DOI: 10.1158/0008-5472.can-10-4475] [Cited by in Crossref: 102] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
37 Fernandez-rozadilla C, Cazier JB, Moreno V, Crous-bou M, Guinó E, Durán G, Lamas MJ, López R, Candamio S, Gallardo E, Paré L, Baiget M, Páez D, López-fernández LA, Cortejoso L, García MI, Bujanda L, González D, Gonzalo V, Rodrigo L, Reñé JM, Jover R, Brea-fernández A, Andreu M, Bessa X, Llor X, Xicola R, Palles C, Tomlinson I, Castellví-bel S, Castells A, Ruiz-ponte C, Carracedo A; on behalf of the EPICOLON Consortium. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J 2013;13:209-17. [DOI: 10.1038/tpj.2012.2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
38 Li D, Wen S. Silencing of lncRNA LINC00346 Inhibits the Proliferation and Promotes the Apoptosis of Colorectal Cancer Cells Through Inhibiting JAK1/STAT3 Signaling. Cancer Manag Res 2020;12:4605-14. [PMID: 32606953 DOI: 10.2147/CMAR.S249491] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Kunjiappan S, Theivendran P, Baskararaj S, Sankaranarayanan B, Palanisamy P, Saravanan G, Arunachalam S, Sankaranarayanan M, Natarajan J, Somasundaram B, Wadhwani A. Modeling a pH-sensitive Zein-co-acrylic acid hybrid hydrogels loaded 5-fluorouracil and rutin for enhanced anticancer efficacy by oral delivery. 3 Biotech 2019;9:185. [PMID: 31065485 DOI: 10.1007/s13205-019-1720-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
40 Bergamo F, Lonardi S, Salmaso B, Lacognata C, Battaglin F, Cavallin F, Saadeh L, Murgioni S, Caruso A, Aliberti C, Zagonel V, Castoro C, Scarpa M. Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients. Acta Oncologica 2018;57:412-9. [DOI: 10.1080/0284186x.2017.1351038] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Aprile G, Ferrari L, Fontanella C, Puglisi F. Bevacizumab in older patients with advanced colorectal or breast cancer. Crit Rev Oncol Hematol 2013;87:41-54. [PMID: 23265855 DOI: 10.1016/j.critrevonc.2012.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]